In a recent study, Etxeberria et al elegantly demonstrated that only the combination of TCR T cells with inmunostimulating agents, such as interleukin (IL)-12 and anti-CD137 mAb, was able to induce a systemic endogenous tumor-specific T-cell response strong enough to reject local and distal tumors.15 Similar findings were observed when ACT was combined with pathogen-based vaccines.14 This evidence concerns the gene TNFRSF9 and neoplasm.